harbi1 Antibody

What is HARBI1 and why is it significant for research?

HARBI1 (harbinger transposase derived 1) is a protein evolutionarily related to transposase components of the Harbinger transposon system. It is also known as C11orf77, FLJ32675, or Harbinger transposase-derived nuclease . The significance of HARBI1 stems from its relationship to mobile genetic elements and its potential role in genome dynamics. Research indicates that HARBI1 interacts with NAIF1 (nuclear apoptosis-inducing factor 1), suggesting functional parallels to transposon components . While HARBI1 itself appears to be deficient in transposition activity, understanding its function can provide insights into the domestication of transposable elements and their integration into host cellular processes.

HARBI1 antibodies exhibit broad cross-reactivity across multiple species as shown in the following comprehensive reactivity profile:

This broad cross-reactivity suggests high conservation of HARBI1 epitopes across species and provides researchers flexibility in comparative studies across different model organisms .

What are the optimal conditions for Western blot detection of HARBI1?

For optimal Western blot detection of HARBI1, researchers should consider the following protocol parameters:

• Antibody Dilution: The recommended working concentration ranges from 0.04-0.4 μg/mL for most commercial HARBI1 antibodies . Begin with a 1:1000 dilution and optimize based on signal strength.

• Sample Preparation: Include protease inhibitors in lysis buffers to prevent degradation. Given HARBI1's potential nuclease activity, phosphatase inhibitors may also be beneficial.

• Gel Percentage: Use 10-12% polyacrylamide gels for optimal resolution of HARBI1 (approximately 34-37 kDa).

• Blocking Conditions: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature is generally effective.

• Signal Enhancement: For low-abundance detection, consider enhanced chemiluminescence (ECL) systems and longer exposure times.

• Controls: Include positive controls from tissues/cells known to express HARBI1, and consider using recombinant HARBI1 protein as a standard.

Optimizing these parameters will help ensure specific detection and minimize background interference in HARBI1 Western blots.

How should researchers optimize immunocytochemistry and immunofluorescence for HARBI1 detection?

For optimal HARBI1 detection in ICC/IF applications, consider these methodological recommendations:

• Antibody Dilution: Start with 0.25-2 μg/mL for immunofluorescence applications . Titration experiments are recommended to determine optimal concentration for your specific cell type.

• Fixation Method: 4% paraformaldehyde (PFA) for 15 minutes at room temperature is generally effective. Compare with methanol fixation which may better preserve certain epitopes.

• Permeabilization: Use 0.1-0.3% Triton X-100 for 10 minutes to facilitate antibody access to intracellular targets.

• Antigen Retrieval: Test if heat-induced epitope retrieval improves signal, especially for formalin-fixed samples.

• Signal Amplification: Consider tyramide signal amplification for low-abundance detection.

• Counterstaining: Co-stain with markers for specific cellular compartments to assess colocalization.

• Controls: Include secondary-only controls and cells where HARBI1 expression is knocked down or absent.

Remember that HARBI1 has been shown to interact with NAIF1 , making co-immunofluorescence with NAIF1 antibodies a potentially interesting approach to study their co-localization or interaction dynamics.

What are the recommended protocols for immunohistochemical detection of HARBI1 in tissue sections?

For effective immunohistochemical detection of HARBI1 in tissue sections:

• Tissue Preparation: Use 10% neutral buffered formalin fixation followed by paraffin embedding. Optimal fixation time should be determined empirically for different tissues.

• Section Thickness: 4-5 μm sections generally provide good resolution for HARBI1 detection.

• Antigen Retrieval: Heat-induced epitope retrieval is recommended, using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0). Compare both to determine optimal conditions.

• Blocking: 5-10% normal serum (from the same species as secondary antibody) for 1 hour at room temperature.

• Primary Antibody Incubation: Dilute according to manufacturer recommendations (validated for paraffin sections) . Overnight incubation at 4°C typically yields optimal results.

• Detection System: Both chromogenic (DAB) and fluorescent detection systems have been validated. Choose based on your experimental needs and available imaging systems.

• Evaluation: HARBI1 expression patterns should be assessed by trained observers, with attention to subcellular localization and tissue distribution patterns.

When interpreting IHC results, consider that HARBI1 expression patterns may vary significantly between tissues and cell types, reflecting its specific biological functions in different contexts.

How can researchers validate the specificity of HARBI1 antibodies?

Rigorous validation of HARBI1 antibody specificity is crucial for research reliability. Implement the following comprehensive validation strategy:

• Western Blot Analysis: Confirm detection of a band at the expected molecular weight (approximately 34-37 kDa). Commercial antibodies have undergone validation against multiple species .

• Peptide Competition Assay: Pre-incubate the antibody with the immunizing peptide before application. Signal elimination confirms specificity.

• Knockout/Knockdown Controls: Compare staining between wild-type samples and those with HARBI1 knocked down (siRNA) or knocked out (CRISPR-Cas9).

• Recombinant Protein Testing: Test antibody against recombinant HARBI1 protein. Some commercial antibodies have been validated against protein arrays containing 364 human recombinant protein fragments to assess cross-reactivity .

• Multiple Antibody Concordance: Compare staining patterns using antibodies raised against different HARBI1 epitopes. Agreement between antibodies suggests specificity.

• Cross-Species Reactivity Assessment: If the protein is conserved, similar staining patterns across species further validates specificity. Commercial HARBI1 antibodies show reactivity across multiple species .

• Mass Spectrometry Confirmation: Immunoprecipitate with the antibody and confirm identity of pulled-down proteins by mass spectrometry.

Implementing these approaches provides a multi-faceted validation strategy that significantly increases confidence in antibody specificity for HARBI1 detection.

What experimental approaches can elucidate HARBI1's interaction with NAIF1 and other potential binding partners?

To investigate HARBI1's protein interactions, particularly with NAIF1, researchers can employ these methodological approaches:

• Co-immunoprecipitation (Co-IP): Previous research demonstrated that HA-tagged HARBI1 efficiently co-precipitates with Myc-tagged NAIF1 . Researchers should:

  • Use epitope-tagged constructs (HA-HARBI1 and Myc-NAIF1)

  • Perform reciprocal Co-IPs (pulling down with anti-HA and anti-Myc)

  • Include appropriate negative controls (unrelated tagged proteins)

• Proximity Ligation Assay (PLA): This technique can visualize protein interactions in situ with high sensitivity.

• Bimolecular Fluorescence Complementation (BiFC): By fusing complementary fragments of a fluorescent protein to HARBI1 and potential interacting partners, interaction brings fragments together to produce fluorescence.

• FRET/BRET Analysis: These energy transfer techniques can detect close proximity between fluorescently labeled proteins.

• Yeast Two-Hybrid Screening: To identify novel interaction partners beyond NAIF1.

• Domain Mapping: Create truncation mutants to identify which domains of HARBI1 are essential for interaction with NAIF1.

• Functional Consequence Assessment: Investigate how disruption of this interaction affects cellular functions using site-directed mutagenesis of interaction interfaces.

The established HARBI1-NAIF1 interaction suggests functional parallels to transposon components , making this research direction particularly relevant for understanding the evolutionary domestication of transposable elements.

How can researchers investigate HARBI1's potential nuclease activity?

To characterize the putative nuclease activity of HARBI1 (its name suggests harbinger transposase-derived nuclease ), researchers should implement these methodological approaches:

• In Vitro Nuclease Assays:

  • Purify recombinant HARBI1 protein (consider MBP-fusion approach as described for related proteins )

  • Incubate with various DNA substrates (linear, circular, single-stranded, double-stranded)

  • Analyze reaction products by gel electrophoresis to detect cleavage patterns

  • Test metal ion dependencies (Mg²⁺, Mn²⁺, Ca²⁺) as nuclease activity often requires specific cofactors

• Mutational Analysis:

  • Identify putative catalytic residues based on sequence alignment with known nucleases

  • Create point mutations and test effects on nuclease activity

  • The catalytic domain is likely related to EC 3.1 enzyme classification

• Substrate Preference Determination:

  • Test sequence specificity using various oligonucleotide substrates

  • Analyze cleavage site preferences through sequencing of reaction products

• Cellular Nuclease Assays:

  • Express wild-type and mutant HARBI1 in cells

  • Assess DNA damage markers (γ-H2AX foci)

  • Perform modified COMET assays to detect DNA fragmentation

• Electrophoretic Mobility Shift Assays (EMSA):

  • Assess DNA binding capacity of HARBI1 using radiolabeled probes

  • Similar approaches have been used for related transposase proteins

• In Vivo Functional Studies:

  • Create HARBI1 knockout cell lines using CRISPR-Cas9

  • Assess phenotypic changes related to DNA metabolism

  • Perform complementation studies with wild-type and mutant HARBI1

These approaches should be integrated to build a comprehensive understanding of HARBI1's nuclease properties and their biological significance.

What are common technical challenges with HARBI1 detection and their solutions?

Researchers commonly encounter these challenges when working with HARBI1 antibodies:

For HARBI1 specifically, researchers should be aware that its evolutionary relationship to nucleases may make it sensitive to specific buffer conditions. Additionally, its interaction with NAIF1 might mask epitopes in some contexts , potentially requiring optimization of extraction conditions.

What controls are essential when working with HARBI1 antibodies?

Implement these essential controls to ensure reliable and interpretable results when working with HARBI1 antibodies:

• Positive Controls:

  • Cell lines or tissues known to express HARBI1

  • Recombinant HARBI1 protein (purified or overexpressed)

  • Validated samples from previous successful experiments

• Negative Controls:

  • Secondary antibody only (omit primary antibody)

  • Isotype control (irrelevant primary antibody of same isotype)

  • HARBI1 knockout or knockdown samples (siRNA, shRNA, or CRISPR)

  • Pre-immune serum (for polyclonal antibodies)

• Specificity Controls:

  • Peptide competition/blocking experiment

  • Multiple antibodies targeting different HARBI1 epitopes

  • Detection in multiple species if studying evolutionarily conserved aspects

• Procedural Controls:

  • Loading controls for Western blot (housekeeping proteins)

  • Autofluorescence controls for immunofluorescence

  • Endogenous peroxidase blocking controls for IHC

• Interaction Studies Controls:

  • When studying HARBI1-NAIF1 interaction, include controls with unrelated proteins (e.g., HARBI1 with Rep78 and NAIF1 with Jazz-SB have been used as negative interaction controls)

Implementing these controls systematically will help distinguish genuine HARBI1 signal from artifacts and enable confident interpretation of experimental results.

How can researchers optimize antibody dilutions for different HARBI1 detection methods?

Systematic antibody dilution optimization is critical for balancing specific signal against background. For HARBI1 antibodies:

• Western Blot Optimization:

  • Start with manufacturer's recommended range (0.04-0.4 μg/mL)

  • Perform serial dilutions (e.g., 1:500, 1:1000, 1:2000, 1:5000)

  • Assess signal-to-noise ratio at each dilution

  • Consider gradient exposure times to determine optimal dilution

  • Document optimal conditions for specific antibody lots

• Immunofluorescence Titration:

  • Begin with recommended range (0.25-2 μg/mL)

  • Test multiple dilutions with consistent exposure settings

  • Evaluate specific signal intensity against background fluorescence

  • Consider cell type-specific optimization (different cell types may require different conditions)

• Immunohistochemistry Optimization:

  • Test dilution series on positive control tissues

  • Compare different antigen retrieval methods at each dilution

  • Assess staining intensity, specificity, and background

  • Optimize secondary antibody dilution independently

  • Document optimal conditions for different tissue types

• Quantitative Considerations:

  • For semi-quantitative applications, ensure signal is in linear range

  • Validate dilution using samples with known HARBI1 expression levels

  • For multiplex applications, optimize each antibody separately then in combination

• Documentation:

  • Create a detailed laboratory protocol with optimized conditions

  • Include images of positive and negative controls at optimal dilutions

  • Record antibody lot numbers associated with specific optimization experiments

This methodical approach ensures reproducible detection of HARBI1 across different experimental platforms while minimizing non-specific background.

How does HARBI1 relate to transposon biology and what experimental approaches can explore this relationship?

HARBI1's evolutionary relationship to transposase proteins opens several research avenues:

• Evolutionary Analysis:

  • HARBI1 is most closely related to the Harbinger3_DR transposase, suggesting evolutionary domestication of a transposon-derived protein

  • Comparative genomics approaches can trace HARBI1 emergence across species

  • Phylogenetic analysis can establish when HARBI1 diverged from active transposases

• Functional Comparison Studies:

  • Unlike active Harbinger transposases, HARBI1 appears deficient in transposition activity

  • Researchers can investigate whether HARBI1 retains other transposase-associated functions (DNA binding, cleavage)

  • Chimeric protein experiments mixing HARBI1 domains with active transposase domains can identify functional constraints

• Interaction Network Analysis:

  • HARBI1 interacts with NAIF1, paralleling the transposase/Myb-like protein interaction in Harbinger elements

  • Protein-protein interaction studies can identify additional partners

  • Compare HARBI1-NAIF1 interaction with transposase-Myb interactions to identify conserved binding interfaces

• Cellular Function Investigation:

  • Examine whether HARBI1 regulates endogenous transposable elements

  • Assess impact of HARBI1 knockout on genome stability

  • Investigate potential domestication for host cellular functions

• Structural Biology Approaches:

  • Determine crystal structure of HARBI1 alone and in complex with NAIF1

  • Compare with transposase structures to identify conserved and divergent features

  • Structure-guided mutagenesis to test functional hypotheses

These approaches can collectively illuminate how a transposon-derived protein has been repurposed throughout evolution, potentially gaining new functions while losing original transposition capacity.

What methodological approaches can examine HARBI1's role in cellular processes beyond transposition?

To investigate HARBI1's functional roles beyond its evolutionary relationship to transposons:

• Transcriptional Regulation Analysis:

  • ChIP-seq to identify potential DNA binding sites (HARBI1's relationship to DNA-binding transposases suggests potential chromatin interactions)

  • RNA-seq following HARBI1 modulation to identify regulated genes

  • Reporter assays to test direct transcriptional effects

• Protein Interaction Network Mapping:

  • Proximity-dependent biotin identification (BioID) or APEX proximity labeling

  • Immunoprecipitation followed by mass spectrometry (IP-MS)

  • Yeast two-hybrid screening for novel interaction partners beyond NAIF1

• Cell Biological Function Assessment:

  • CRISPR-Cas9 knockout/knockin models

  • Phenotypic screens (proliferation, migration, differentiation)

  • Stress response profiling (DNA damage, oxidative stress, etc.)

  • Cell cycle analysis to detect potential regulatory roles

• Subcellular Localization Studies:

  • High-resolution imaging with co-localization markers

  • Fractionation studies to determine compartmentalization

  • Stimulus-dependent localization changes

• Post-translational Modification Analysis:

  • Mass spectrometry to identify modifications

  • Pharmacological modulation of signaling pathways

  • Mutational analysis of modification sites

• Tissue-specific Expression Profiling:

  • IHC across tissue panels to determine expression patterns

  • Single-cell RNA-seq to identify cell-type specific expression

  • Developmental time course studies

These methodologies provide complementary approaches to uncover HARBI1's functional roles beyond its evolutionary connection to transposons, potentially revealing how domesticated transposase proteins acquire new cellular functions.

How can researchers investigate potential roles of HARBI1 in human health and disease?

To explore HARBI1's potential implications in human health and disease contexts:

• Expression Analysis in Disease States:

  • Compare HARBI1 expression levels across healthy and diseased tissues using validated antibodies

  • Analyze public databases (TCGA, GTEx) for expression correlations with disease phenotypes

  • Perform tissue microarray analysis with HARBI1 antibodies across disease cohorts

• Genetic Association Studies:

  • Examine GWAS datasets for HARBI1 locus associations with diseases

  • Analyze potential impact of SNPs on HARBI1 expression or function

  • Investigate copy number variations affecting HARBI1

• Functional Disease Modeling:

  • Create disease-relevant cell models with HARBI1 modification

  • Assess impact of disease-associated mutations on HARBI1 function

  • Test whether HARBI1 modulation affects disease-relevant cellular phenotypes

• Mechanistic Studies:

  • Investigate whether HARBI1-NAIF1 interaction is altered in disease contexts

  • Examine potential roles in genome stability given its transposase ancestry

  • Assess effects on cellular stress responses and DNA repair pathways

• Therapeutic Potential Assessment:

  • Evaluate HARBI1 as a potential biomarker using validated antibodies

  • Explore druggability of HARBI1 or its interaction interfaces

  • Investigate whether transposon-derived proteins like HARBI1 represent a novel class of therapeutic targets

• Impact on Mobile Genetic Elements:

  • Analyze whether HARBI1 regulates endogenous transposable element activity in disease contexts

  • Investigate interactions with viral life cycles given evolutionary connections to DNA-handling proteins

These research directions could uncover previously unrecognized roles for HARBI1 in human health and potentially identify novel therapeutic strategies targeting this evolutionarily distinctive protein.